NextCure Positions Dual ADC Candidates as ADC Meta Intensifies in Oncology

As the ADC (antibody-drug conjugate) meta accelerates across the biotech landscape, NextCure Inc. (NXTC) is making tangible progress with its dual-candidate pipeline while maintaining a solid financial footing. The company’s cash position of $41.8 million as of year-end 2025 extends its operational runway into the first half of 2027, providing the runway necessary to advance two distinct ADC programs targeting underserved cancer indications.

The biotechnology firm’s strategic focus centers on solid tumors with significant unmet medical needs, particularly within gynecological and breast cancer segments where emerging biomarkers CDH6 and B7-H4 represent promising therapeutic opportunities. Both investigational ADCs—SIM0505 and LNCB74—are progressing through dose-escalation Phase 1 studies designed to establish tolerability profiles, optimal dosing windows, and preliminary efficacy signals.

SIM0505: CDH6-Directed ADC Approaching Efficacy Readout

SIM0505 represents NextCure’s first ADC candidate, engineered to target cadherin-6, an antigen overexpressed across multiple solid tumors while maintaining minimal presence in normal tissue compartments. The compound leverages a proprietary topoisomerase-1 inhibitor payload formulated to deliver potent anti-tumor activity coupled with rapid clearance kinetics from systemic circulation.

The ongoing open-label Phase 1 trial is enrolling patients with advanced solid tumors, with particular emphasis on platinum-resistant ovarian cancer populations. Clinical data readout is anticipated in Q2 2026, consolidating results from patient cohorts spanning both U.S. and Chinese study sites. To prepare for dose-optimization initiation in early 2026, NextCure is actively expanding clinical trial sites and augmenting drug supply chain capacity. The company retains global development rights outside the Greater China region (mainland China, Hong Kong, Macau, and Taiwan), where co-development partner Simcere Zaiming maintains territorial exclusivity.

LNCB74: B7-H4 Program Accelerates into Higher Dosing Cohorts

LNCB74 targets B7-H4, another cancer-associated immune checkpoint antigen with similarly restricted expression in normal tissues. This ADC utilizes a tumor-selective cleavable linker platform combined with an MMAE payload to enhance targeted cytotoxicity and therapeutic selectivity. Following a protocol amendment in November 2025, dosing has progressed into elevated-dose cohorts, signaling accelerating trial momentum.

Patient enrollment prioritizes individuals with elevated B7-H4 expression in breast and gynecological malignancies, while also including adenoid cystic carcinoma populations. Original expectations for proof-of-concept data in the first half of 2026 have been adjusted to accommodate expanded enrollment strategies, with a comprehensive trial progress update now anticipated in the second half of 2026. NextCure co-shares global development rights with partner LigaChem Biosciences under a balanced 50-50 cost-sharing arrangement, distributing both financial and operational responsibilities.

Financial Runway and Market Position

NextCure’s interim cash, equivalents, and marketable securities totaled approximately $41.8 million as of December 31, 2025 (subject to audit finalization). This capital base is expected to sustain planned development activities through the first half of 2027, a timeline that aligns with critical clinical milestones for both ADC candidates. Over the past 12 months, NXTC shares have traded within a $2.69 to $15.74 range, recently closing around $12.65—reflecting ongoing market assessment of the company’s clinical trajectory and ADC meta dynamics within the broader biotech sector.